Crizotinib is launched in China
Crizotinib has been approved for marketing in China and is mainly used for the treatment of ALK positive non-small cell lung cancer. Patients need to purchase it through formal channels and strictly follow medical advice.
1. Listing status
(1) Approval time: crizotinib was approved in China in 2013 and is the first ALK inhibitor to be marketed domestically.
(2) Indications: Currently approved for first-line treatment of ALK positive advanced non-small cell lung cancer.
2. Medication Standards
(1) Prescription requirement: A prescription must be issued by a specialist oncologist and purchased from a qualified medical institution.
(2) Dosage standard: The recommended dosage is 250mg orally twice a day, and it should be swallowed whole.
3 purchasing channels
(1) Regular channels: can be purchased through the oncology department of a tertiary hospital or large chain pharmacies.
(2) Anti counterfeiting key points: It is necessary to verify the approval number H20153211 of the national drug standard on the drug packaging.
4 Precautions
(1) Adverse reactions: Common visual impairment, nausea and vomiting, etc. Regular monitoring of liver function is necessary.
(2) Taboo population: Patients with severe liver and kidney dysfunction need to adjust the dosage, and are prohibited during pregnancy.
- Previous:Is Crizotinib effective
- Next:Has Crizotinib been launched in China
Disclaimer：《Crizotinib is launched in China》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！